Top

BMC Cardiovascular Disorders

Published in:

01-12-2021 | Myocardial Infarction | Research article

SCD leads to the development and progression of acute myocardial infarction through the AMPK signaling pathway

Authors: Lijie Wang, Fengxia Yu

Published in: BMC Cardiovascular Disorders | Issue 1/2021

Abstract

Background

Acute myocardial infarction (AMI) is myocardial necrosis caused by acute coronary ischemia and hypoxia. It can be complicated by arrhythmia, shock, heart failure and other symptoms that can be life-threatening. A multi-regulator driven dysfunction module for AMI was constructed. It is intended to explore the pathogenesis and functional pathways regulation of acute myocardial infarction.

Methods

Combining differential expression analysis, co-expression analysis, and the functional enrichment analysis, a set of expression disorder modules related to AMI was obtained. Hypergeometric test was performed to calculate the potential regulatory effects of multiple factors on the module, identifying a range of non-coding RNA and transcription factors.

Results

A total of 4551 differentially expressed genes for AMI and seven co-expression modules were obtained. These modules are primarily involved in the metabolic processes of prostaglandin transport processes, regulating DNA recombination and AMPK signal transduction. Based on this set of functional modules, 3 of 24 transcription factors (TFs) including NFKB1, MECP2 and SIRT1, and 3 of 782 non-coding RNA including miR-519D-3P, TUG1 and miR-93-5p were obtained. These core regulators are thought to be involved in the progression of AMI disease. Through the AMPK signal transduction, the critical gene stearoyl-CoA desaturase (SCD) can lead to the occurrence and development of AMI.

Conclusions

In this study, a dysfunction module was used to explore the pathogenesis of multifactorial mediated AMI and provided new methods and ideas for subsequent research. It helps researchers to have a deeper understanding of its potential pathogenesis. The conclusion provides a theoretical basis for biologists to design further experiments related to AMI.

Available only for authorised users

Acharya D. Predictors of outcomes in myocardial infarction and cardiogenic shock. Cardiol Rev. 2018;26:255–66.PubMedPubMedCentralCrossRef

Arora G, Bittner V. Chest pain characteristics and gender in the early diagnosis of acute myocardial infarction. Curr Cardiol Rep. 2015;17:5.PubMedCrossRef

Sinclair D. Myocardial infarction. Considerations for geriatric patients. Can Fam Phys. 1994;40:1172–7.

Yang EH, Brilakis ES, Reeder GS, Gersh BJ. Modern management of acute myocardial infarction. Curr Probl Cardiol. 2006;31:769–817.PubMedCrossRef

Liu ZB, Fu XH, Wei G, Gao JL. Cytochrome c release in acute myocardial infarction predicts poor prognosis and myocardial reperfusion on contrast-enhanced magnetic resonance imaging. Coron Artery Dis. 2014;25:66–72.PubMedCrossRef

Mullasari AS, Balaji P, Khando T. Managing complications in acute myocardial infarction. J Assoc Phys India. 2011;59(Suppl):43–8.

Scroggins NM. Recognition and management of inferior wall myocardial infarctions and right ventricular infarcts. J Infus Nurs. 2001;24:263–7.PubMedCrossRef

Bounhoure JP, Ouldzen H, Carrie D, Alibelli MJ, Puel J. Myocardial infarction with angiographically normal coronary arteries myth or reality? Bull Acad Natl Med. 2007;191:815–24 (discussion 24–25).PubMed

Klem I, Kim RJ. Assessment of microvascular injury after acute myocardial infarction: the importance of the area at risk. Nat Clin Pract Cardiovasc Med. 2008;5:756–7.PubMedCrossRef

10.

Hebsur S, Vakil E, Oetgen WJ, Kumar PN, Lazarous DF. Influenza and coronary artery disease: exploring a clinical association with myocardial infarction and analyzing the utility of vaccination in the prevention of myocardial infarction. Rev Cardiovasc Med. 2014;15:168–75.PubMed

11.

Alpert JS, Thygesen KA, White HD, Jaffe AS. Diagnostic and therapeutic implications of type 2 myocardial infarction: review and commentary. Am J Med. 2014;127:105–8.PubMedCrossRef

12.

Jacoby RM, Nesto RW. Acute myocardial infarction in the diabetic patient: pathophysiology, clinical course, and prognosis. J Am Coll Cardiol. 1992;20:736–44.PubMedCrossRef

13.

Lee SI, Lee SY, Choi CH, Park KY, Park CH. Left heart decompression in acute complicated myocardial infarction during extracorporeal membrane oxygenation. J Intensive Care Med. 2017;32:405–8.PubMedCrossRef

14.

Graf T, Desch S, Eitel I, Thiele H. Acute myocardial infarction and cardiogenic shock: pharmacologic and mechanical hemodynamic support pathways. Coron Artery Dis. 2015;26:535–44.PubMedCrossRef

15.

Aymong ED, Ramanathan K, Buller CE. Pathophysiology of cardiogenic shock complicating acute myocardial infarction. Med Clin N Am. 2007;91:701–12.PubMedCrossRef

16.

Norton M, Letizia M, Jennrich JA. Right ventricular infarction vs. left ventricular infarction: a review of pathophysiology, medical treatment, and nursing care. Medsurg Nurs. 1993;2:203–9.PubMed

17.

Pollard TJ. The acute myocardial infarction. Prim Care. 2000;27(631–49):vi.

18.

Bolognese L. Changing patterns of ST-elevation myocardial infarction epidemiology. Am Heart J. 2010;160:S1–3.PubMedCrossRef

19.

Gupta T, Harikrishnan P, Kolte D, Khera S, Aronow WS, Mujib M, Palaniswamy C, Sule S, Jain D, Ahmed A, Lanier GM, Cooper HA, Frishman WH, Fonarow GC, Panza JA. Outcomes of acute myocardial infarction in patients with hypertrophic cardiomyopathy. Am J Med. 2015;128(879–887):e1.

20.

Tomcsanyi J, Tako K, Sharman B. Recurrent acute myocardial infarction as a thromboembolic complication of atrial fibrillation. Orv Hetil. 2016;157:191–3.PubMedCrossRef

21.

Flapan AD. Management of patients after their first myocardial infarction. BMJ. 1994;309:1129–34.PubMedPubMedCentralCrossRef

22.

Jariwala P, Chandra S. Diagnosis and management of failed thrombolytic therapy for acute myocardial infarction. Indian Heart J. 2010;62:21–8.PubMed

23.

Bovenzi F, De Luca L, de Luca I. Which is the best reperfusion strategy for patients with high-risk myocardial infarction? Ital Heart J. 2004;5(Suppl 6):83S-91S.PubMed

24.

Mintz E. Emergency department management of acute myocardial infarction. Mt Sinai J Med. 1997;64:258–74.PubMed

25.

Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, Holko M, Yefanov A, Lee H, Zhang N, Robertson CL, Serova N, Davis S, Soboleva A. NCBI GEO: archive for functional genomics data sets–update. Nucleic Acids Res. 2013;41:D991–5.PubMedCrossRef

26.

Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.PubMedPubMedCentralCrossRef

27.

Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinf. 2008;9:559.CrossRef

28.

Yu G, Wang LG, Han Y, He QY. Cluster profiler: an R package for comparing biological themes among gene clusters. Omics J integr Biol. 2012;16:284–7.CrossRef

29.

Carlin DE, Demchak B, Pratt D, Sage E, Ideker T. Network propagation in the cytoscape cyberinfrastructure. PLoS Comput Biol. 2017;13:e1005598.PubMedPubMedCentralCrossRef

30.

Han H, Cho JW, Lee S, Yun A, Kim H, Bae D, Yang S, Kim CY, Lee M, Kim E, Lee S, Kang B, Jeong D, Kim Y, Jeon HN, Jung H, Nam S, Chung M, Kim JH, Lee I. TRRUST v2: an expanded reference database of human and mouse transcriptional regulatory interactions. Nucleic Acids Res. 2018;46:D380–6.PubMedCrossRef

31.

Yi Y, Zhao Y, Li C, Zhang L, Huang H, Li Y, Liu L, Hou P, Cui T, Tan P, Hu Y, Zhang T, Huang Y, Li X, Yu J, Wang D. RAID v2.0: an updated resource of RNA-associated interactions across organisms. Nucleic Acids Res. 2017;45:D115–8.PubMedCrossRef

32.

Kloner RA, Dai W, Hale SL, Shi J. Approaches to Improving cardiac structure and function during and after an acute myocardial infarction: acute and chronic phases. J Cardiovasc Pharmacol Ther. 2016;21:363–7.PubMedCrossRef

33.

Grisel P, Roffi M, Muller H, Keller PF. Mechanical complications of myocardial infarction. Rev Med Suisse Romande. 2011;7:1189–92.

34.

Silvain J, Collet JP, Guedeney P, Varenne O, Nagaswami C, Maupain C, Empana JP, Boulanger C, Tafflet M, Manzo-Silberman S, Kerneis M, Brugier D, Vignolles N, Weisel JW, Jouven X, Montalescot G, Spaulding C. Thrombus composition in sudden cardiac death from acute myocardial infarction. Resuscitation. 2017;113:108–14.PubMedCrossRef

35.

Pasupathy S, Tavella R, Grover S, Raman B, Procter NEK, Du YT, Mahadavan G, Stafford I, Heresztyn T, Holmes A, Zeitz C, Arstall M, Selvanayagam J, Horowitz JD, Beltrame JF. Early use of N-acetylcysteine with nitrate therapy in patients undergoing primary percutaneous coronary intervention for ST-Segment-elevation myocardial infarction reduces myocardial infarct size (the NICAM Trial [N-acetylcysteine in Acute Myocardial Infarction]). Circulation. 2017;136:894–903.PubMedCrossRef

36.

Yang H, Sun W, Quan N, Wang L, Chu D, Cates C, Liu Q, Zheng Y, Li J. Cardioprotective actions of Notch1 against myocardial infarction via LKB1-dependent AMPK signaling pathway. Biochem Pharmacol. 2016;108:47–57.PubMedPubMedCentralCrossRef

37.

Boccardi V, Rizzo MR, Marfella R, Papa M, Esposito A, Portoghese M, Paolisso G, Barbieri M. 94 ins/del ATTG NFKB1 gene variant is associated with lower susceptibility to myocardial infarction. Nutr Metab Cardiovasc Dis. 2011;21:679–84.PubMedCrossRef

38.

Feng Y, Huang W, Wani M, Yu X, Ashraf M. Ischemic preconditioning potentiates the protective effect of stem cells through secretion of exosomes by targeting Mecp2 via miR-22. PLoS ONE. 2014;9:e88685.PubMedPubMedCentralCrossRef

39.

Ding M, Lei J, Han H, Li W, Qu Y, Fu E, Wang X. SIRT1 protects against myocardial ischemia-reperfusion injury via activating eNOS in diabetic rats. Cardiovasc Diabetol. 2015;14:143.PubMedPubMedCentralCrossRef

40.

Yang G, Weng X, Zhao Y, Zhang X, Hu Y, Dai X, Liang P, Wang P, Ma L, Sun X, Hou L, Xu H, Fang M, Li Y, Jenuwein T, Xu Y, Sun A. The histone H3K9 methyltransferase SUV39H links SIRT1 repression to myocardial infarction. Nat Commun. 2017;8:14941.PubMedPubMedCentralCrossRef

41.

Zhang D, Wang B, Ma M, Yu K, Zhang Q, Zhang X. LncRNA HOTAIR protects myocardial infarction rat by sponging miR-519d-3p. J Cardiovasc Transl Res. 2019;12:171–83.PubMedCrossRef

42.

Jiang N, Xia J, Jiang B, Xu Y, Li Y. TUG1 alleviates hypoxia injury by targeting miR-124 in H9c2 cells. Biomed Pharmacother. 2018;103:1669–77.PubMedCrossRef

43.

Liu J, Jiang M, Deng S, Lu J, Huang H, Zhang Y, Gong P, Shen X, Ruan H, Jin M, Wang H. MiR-93-5p-containing exosomes treatment attenuates acute myocardial infarction-induced myocardial damage. Mol Ther Nucleic Acids. 2018;11:103–15.PubMedPubMedCentralCrossRef

44.

Sasso FC, Pafundi PC, Marfella R, et al. Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: the prospective AIRE Study. Cardiovasc Diabetol. 2019;18(1):24. https://doi.org/10.1186/s12933-019-0826-0.CrossRefPubMedPubMedCentral

45.

Marfella R, Sasso FC, Siniscalchi M, et al. Peri-procedural tight glycemic control during early percutaneous coronary intervention is associated with a lower rate of in-stent restenosis in patients with acute ST-elevation myocardial infarction. J Clin Endocrinol Metab. 2012;97(8):2862–71. https://doi.org/10.1210/jc.2012-1364.CrossRefPubMed

46.

Marfella R, Sasso FC, Cacciapuoti F, et al. Tight glycemic control may increase regenerative potential of myocardium during acute infarction. J Clin Endocrinol Metab. 2012;97(3):933–42. https://doi.org/10.1210/jc.2011-2037.CrossRefPubMed

47.

Marfella R, Ferraraccio F, Rizzo MR, et al. Innate immune activity in plaque of patients with untreated and L-thyroxine-treated subclinical hypothyroidism. J Clin Endocrinol Metab. 2011;96(4):1015–20. https://doi.org/10.1210/jc.2010-1382.CrossRefPubMed

48.

Marfella R, D’ Amico M, Di Filippo C, et al. The possible role of the ubiquitin proteasome system in the development of atherosclerosis in diabetes. Cardiovasc Diabetol. 2007;6:35. https://doi.org/10.1186/1475-2840-6-35.CrossRefPubMedPubMedCentral

49.

Torella D, Ellison GM, Torella M, et al. Carbonic anhydrase activation is associated with worsened pathological remodeling in human ischemic diabetic cardiomyopathy. J Am Heart Assoc. 2014;3(2):e000434. https://doi.org/10.1161/JAHA.113.000434.CrossRefPubMedPubMedCentral

Title: SCD leads to the development and progression of acute myocardial infarction through the AMPK signaling pathway
Authors: Lijie Wang
Fengxia Yu
Publication date: 01-12-2021
Publisher: BioMed Central
Keyword: Myocardial Infarction
Published in: BMC Cardiovascular Disorders / Issue 1/2021
Electronic ISSN: 1471-2261
DOI: https://doi.org/10.1186/s12872-021-02011-8

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

SCD leads to the development and progression of acute myocardial infarction through the AMPK signaling pathway

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Comparison of the effectiveness of position change for patients with pain and vascular complications after transfemoral coronary angiography: a randomized clinical trial

de Winter syndrome or inferior STEMI?

Adherence to prescription guidelines and achievement of treatment goals among persons with coronary heart disease in Tromsø 7

Correction to: Selenium supplementation in patients with peripartum cardiomyopathy: a proof‑of‑concept trial

Clinical characteristics and therapeutic strategy of frequent accelerated idioventricular rhythm

Predictive value of CHADS2 and CHA2DS2-VASc scores for coronary artery lesions and in-hospital prognosis of patients with acute ST-segment elevation myocardial infarction

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page